| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DNA Stock Overview
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming.
Ginkgo Bioworks Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.68 |
| 52 Week High | US$15.86 |
| 52 Week Low | US$2.09 |
| Beta | 0 |
| 1 Month Change | -21.18% |
| 3 Month Change | -36.49% |
| 1 Year Change | -72.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.52% |
Recent News & Updates
Ginkgo Bioworks: Leading Platform But Questionable Business Model
Extremely ambitious objectives have fueled a relatively large market capitalization before the company has really achieved anything significant. Most synthetic biology companies appear to be taking similar approaches to product development and it is unclear whether Ginkgo really has a sustainable competitive advantage. Even after the recent price decline, Ginkgo remains expensive and vulnerable to further fall if sentiment deteriorates.
Shareholder Returns
| DNA | US Chemicals | US Market | |
|---|---|---|---|
| 7D | 10.3% | 2.0% | -0.5% |
| 1Y | -72.8% | -3.4% | -12.3% |
Return vs Industry: DNA underperformed the US Chemicals industry which returned -4.1% over the past year.
Return vs Market: DNA underperformed the US Market which returned -12.9% over the past year.
Price Volatility
| DNA volatility | |
|---|---|
| DNA Average Weekly Movement | 16.4% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: DNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: DNA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 641 | Jason Kelly | https://www.ginkgobioworks.com |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Ginkgo Bioworks Holdings Fundamentals Summary
| DNA fundamental statistics | |
|---|---|
| Market Cap | US$4.76b |
| Earnings (TTM) | -US$2.35b |
| Revenue (TTM) | US$438.15m |
10.9x
P/S Ratio-2.0x
P/E RatioIs DNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNA income statement (TTM) | |
|---|---|
| Revenue | US$438.15m |
| Cost of Revenue | US$191.42m |
| Gross Profit | US$246.72m |
| Other Expenses | US$2.59b |
| Earnings | -US$2.35b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.32 |
| Gross Margin | 56.31% |
| Net Profit Margin | -535.66% |
| Debt/Equity Ratio | 0% |
How did DNA perform over the long term?
See historical performance and comparisonValuation
Is Ginkgo Bioworks Holdings undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
3.01x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DNA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DNA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: DNA is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.
PE vs Market: DNA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DNA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DNA is overvalued based on its PB Ratio (3x) compared to the US Chemicals industry average (2.2x).
Future Growth
How is Ginkgo Bioworks Holdings forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
61.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNA's revenue (31.9% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: DNA's revenue (31.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DNA is forecast to be unprofitable in 3 years.
Past Performance
How has Ginkgo Bioworks Holdings performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-1,239.6%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: DNA is currently unprofitable.
Growing Profit Margin: DNA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DNA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare DNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNA is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (31.5%).
Return on Equity
High ROE: DNA has a negative Return on Equity (-145.87%), as it is currently unprofitable.
Financial Health
How is Ginkgo Bioworks Holdings's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: DNA's short term assets ($1.7B) exceed its short term liabilities ($159.2M).
Long Term Liabilities: DNA's short term assets ($1.7B) exceed its long term liabilities ($284.4M).
Debt to Equity History and Analysis
Debt Level: DNA is debt free.
Reducing Debt: DNA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DNA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 42.7% each year
Dividend
What is Ginkgo Bioworks Holdings's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DNA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DNA has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Jason Kelly (40 yo)
no data
Tenure
US$380,742,276
Compensation
Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly Founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) since 2008 and serves as its Chief Executive Officer and has served as Di...
CEO Compensation Analysis
Compensation vs Market: Jason's total compensation ($USD380.74M) is above average for companies of similar size in the US market ($USD6.86M).
Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: DNA's management team is considered experienced (4.6 years average tenure).
Board Members
Experienced Board: DNA's board of directors are considered experienced (4.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Top Shareholders
Company Information
Ginkgo Bioworks Holdings, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Ginkgo Bioworks Holdings, Inc.
- Ticker: DNA
- Exchange: NYSE
- Founded: 2008
- Industry: Specialty Chemicals
- Sector: Materials
- Implied Market Cap: US$4.761b
- Shares outstanding: 1.78b
- Website: https://www.ginkgobioworks.com
Number of Employees
Location
- Ginkgo Bioworks Holdings, Inc.
- 27 Drydock Avenue
- 8th Floor
- Boston
- Massachusetts
- 2210
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/24 00:00 |
| End of Day Share Price | 2022/05/23 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.